Try our beta test site

Special Survey for Long Term Application

This study has been completed.
Information provided by:
Novo Nordisk A/S Identifier:
First received: January 19, 2012
Last updated: June 26, 2012
Last verified: January 2012
This study is conducted in Japan. The aim of this study is to assess the incidence rate of adverse drug reactions (ADRs) when using somatropin (Norditropin®) for treatment of for achondroplasia without epiphyseal line closure under normal clinical practice conditions.

Condition Intervention
Genetic Disorder
Drug: somatropin

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Specific Survey of Norditropin® in Achondroplasia: Survey for Long-term Application

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Incidence of adverse drug reactions (ADRs)

Secondary Outcome Measures:
  • Treatment evaluation using the Foundation for Growth Science's Criteria for Treatment Continuation: Definitely effective, effective, ineffective or definitely ineffective

Enrollment: 395
Study Start Date: May 1997
Study Completion Date: March 2007
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Somatropin Drug: somatropin
Prescription of somatropin at the discretion of the physician


Ages Eligible for Study:   1 Year to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients being treated with somatropin for achondroplasia without epiphyseal line closure

Inclusion Criteria:

  • Achondroplasia without epiphyseal line closure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01516229

Tokyo, Japan, 103
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Masayuki Senda Novo Nordisk Pharma Ltd.
  More Information

Additional Information:
Responsible Party: Public Access to Clinical Trials, Novo Nordisk A/S Identifier: NCT01516229     History of Changes
Other Study ID Numbers: GH-1941 
Study First Received: January 19, 2012
Last Updated: June 26, 2012

Additional relevant MeSH terms:
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Genetic Diseases, Inborn processed this record on February 20, 2017